Oncology Letters · 2018 · 11 citations · 16 references
MedicineOncologyRadiation OncologyChemotherapyGynecologic OncologyGynecologic Radiation OncologyGynecologic Cancer RadiotherapyImage-guided RadiotherapyIntensity-modulated RadiotherapyOvarian CancerPositron Emission TomographyRadiation TherapyCurative InterventionCurative TherapyImage-guided Intensity-modulated RadiotherapyOvarian Cancer ChemotherapyOvarian Cancer RadiotherapyOvarian Cancer TreatmentRadiation Dose OptimizationRecurrent Ovarian Cancer
The aim of the present study was to evaluate the curative effect of fludeoxyglucose‑positron emission tomography/computed tomography (18F‑FDG‑PET/CT)‑guided intensity‑modulated radiotherapy (IMRT) for 42 patients with International Federation of Gynecology and Obstetrics (FIGO) stage III/IV ovarian cancer. Between January 2012 and December 2015, 42 patients with FIGO stage III/IV ovarian cancer who were treated with 18F‑FDG‑PET/CT‑guided IMRT at the Department of Radiation Oncology were analyzed. A total of 21 patients who exhibited recurrence following surgery and 11 patients who were unable to tolerate or rejected surgery received 5‑10 cycles of chemotherapy only. A total of 10 patients, who were either older (>70 years) or in poor general health were unable to undergo surgery and only received IMRT. The patients received a total radiation dose of 5,040 cGy (range, 4,500‑5,500 cGy), with a dose fraction of 200 cGy/fx, administered a total of 10‑14 times, 5 times/week, prior to being rested for half an hour to relocate lesions and undergoing a second round of radiotherapy for 10‑14 cycles. The 1‑, 2‑ and 3‑year progression‑free survival (PFS) rates of the patients were 66.7, 33.3 and 21.4%, respectively, and the median PFS time was 20.3 months. The 1‑, 2‑ and 3‑year local control rates of the patients were 90.5, 83.3 and 69.0%, respectively, and the 1‑, 2‑ and 3‑year overall survival (OS) rates were 73.8, 64.3 and 52.4%, respectively. According to the results of multivariate analysis using the Cox proportional hazards model, the Karnofsky performance status (KPS) score (1) was the only index associated with prognosis (P<0.003). The study concluded that for patients with advanced ovarian cancer, particularly for patients unable to undergo surgery or chemotherapy, 18F‑FDG PET/CT‑guided IMRT is a safe and effective treatment method, and it may be considered as an equally effective treatment option. Furthermore, the results of the present study suggested that the KPS score of a patient is the only factor affecting the OS time.
16
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote, Claes G. Tropé, Frédéric Amant et al. · New England Journal of Medicine · 2010 · 2.5K citations · Full text
APM Heintz, Franco Odicino, Patrick Maisonneuve et al. · International Journal of Gynecology & Obstetrics · 2006 · 1.3K citations
Medicine, Gynecology, Oncology +10
Bengt Sorbe · International Journal of Gynecological Cancer · 2003 · 101 citations
A.J. Dembo, R. S. Bush, F. A. Beale et al. · PubMed · 1979 · 87 citations